These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
707 related articles for article (PubMed ID: 17192846)
1. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. Caraglia M; Marra M; Leonetti C; Meo G; D'Alessandro AM; Baldi A; Santini D; Tonini G; Bertieri R; Zupi G; Budillon A; Abbruzzese A J Cell Physiol; 2007 May; 211(2):533-43. PubMed ID: 17192846 [TBL] [Abstract][Full Text] [Related]
2. The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate. Caraglia M; D'Alessandro AM; Marra M; Giuberti G; Vitale G; Viscomi C; Colao A; Prete SD; Tagliaferri P; Tassone P; Budillon A; Venuta S; Abbruzzese A Oncogene; 2004 Sep; 23(41):6900-13. PubMed ID: 15286715 [TBL] [Abstract][Full Text] [Related]
3. The farnesyltransferase inhibitor R115777 (ZARNESTRA) enhances the pro-apoptotic activity of interferon-alpha through the inhibition of multiple survival pathways. Caraglia M; Marra M; Viscomi C; D'Alessandro AM; Budillon A; Meo G; Arra C; Barbieri A; Rapp UR; Baldi A; Tassone P; Venuta S; Abbruzzese A; Tagliaferri P Int J Cancer; 2007 Nov; 121(10):2317-30. PubMed ID: 17657738 [TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid produces antitumor effects on mesothelioma through apoptosis and S-phase arrest in p53-independent and Ras prenylation-independent manners. Okamoto S; Kawamura K; Li Q; Yamanaka M; Yang S; Fukamachi T; Tada Y; Tatsumi K; Shimada H; Hiroshima K; Kobayashi H; Tagawa M J Thorac Oncol; 2012 May; 7(5):873-82. PubMed ID: 22481236 [TBL] [Abstract][Full Text] [Related]
5. Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways. Bruzzese F; Pucci B; Milone MR; Ciardiello C; Franco R; Chianese MI; Rocco M; Di Gennaro E; Leone A; Luciano A; Arra C; Santini D; Caraglia M; Budillon A Cell Death Dis; 2013 Oct; 4(10):e878. PubMed ID: 24157872 [TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid but not somatostatin analogs exerts anti-tumor effects in a model of murine prostatic neuroendocrine carcinoma of the development of castration-resistant prostate cancer. Hashimoto K; Masumori N; Tanaka T; Maeda T; Kobayashi K; Kitamura H; Hirata K; Tsukamoto T Prostate; 2013 Apr; 73(5):500-11. PubMed ID: 22996996 [TBL] [Abstract][Full Text] [Related]
8. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation. Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043 [TBL] [Abstract][Full Text] [Related]
9. Induction of apoptosis in prostate cancer cells by pachymic acid from Poria cocos. Gapter L; Wang Z; Glinski J; Ng KY Biochem Biophys Res Commun; 2005 Jul; 332(4):1153-61. PubMed ID: 15913545 [TBL] [Abstract][Full Text] [Related]
10. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. Ray S; Almasan A Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654 [TBL] [Abstract][Full Text] [Related]
11. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer. Bianco R; Caputo R; Caputo R; Damiano V; De Placido S; Ficorella C; Agrawal S; Bianco AR; Ciardiello F; Tortora G Clin Cancer Res; 2004 Jul; 10(14):4858-64. PubMed ID: 15269162 [TBL] [Abstract][Full Text] [Related]
12. Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells. Marra M; Santini D; Meo G; Vincenzi B; Zappavigna S; Baldi A; Rosolowski M; Tonini G; Loeffler M; Lupu R; Addeo SR; Abbruzzese A; Budillon A; Caraglia M Int J Cancer; 2009 Nov; 125(9):2004-13. PubMed ID: 19530242 [TBL] [Abstract][Full Text] [Related]
13. Isorhapontigenin induced cell growth inhibition and apoptosis by targeting EGFR-related pathways in prostate cancer. Zhu C; Zhu Q; Wu Z; Yin Y; Kang D; Lu S; Liu P J Cell Physiol; 2018 Feb; 233(2):1104-1119. PubMed ID: 28422286 [TBL] [Abstract][Full Text] [Related]
14. Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression. Kochuparambil ST; Al-Husein B; Goc A; Soliman S; Somanath PR J Pharmacol Exp Ther; 2011 Feb; 336(2):496-505. PubMed ID: 21059805 [TBL] [Abstract][Full Text] [Related]
15. Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells. Karabulut B; Erten C; Gul MK; Cengiz E; Karaca B; Kucukzeybek Y; Gorumlu G; Atmaca H; Uzunoglu S; Sanli UA; Baran Y; Uslu R Cell Biol Int; 2009 Feb; 33(2):239-46. PubMed ID: 19103299 [TBL] [Abstract][Full Text] [Related]
16. Beta-sitosterol-induced-apoptosis is mediated by the activation of ERK and the downregulation of Akt in MCA-102 murine fibrosarcoma cells. Moon DO; Lee KJ; Choi YH; Kim GY Int Immunopharmacol; 2007 Aug; 7(8):1044-53. PubMed ID: 17570321 [TBL] [Abstract][Full Text] [Related]
17. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice. Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909 [TBL] [Abstract][Full Text] [Related]
18. Acacetin (5,7-dihydroxy-4'-methoxyflavone) exhibits in vitro and in vivo anticancer activity through the suppression of NF-κB/Akt signaling in prostate cancer cells. Kim HR; Park CG; Jung JY Int J Mol Med; 2014 Feb; 33(2):317-24. PubMed ID: 24285354 [TBL] [Abstract][Full Text] [Related]
19. Eriocalyxin B induces apoptosis in lymphoma cells through multiple cellular signaling pathways. Zhang YW; Jiang XX; Chen QS; Shi WY; Wang L; Sun HD; Shen ZX; Chen Z; Chen SJ; Zhao WL Exp Hematol; 2010 Mar; 38(3):191-201. PubMed ID: 20045442 [TBL] [Abstract][Full Text] [Related]
20. Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status. Kato J; Futamura M; Kanematsu M; Gaowa S; Mori R; Tanahashi T; Matsuhashi N; Yoshida K Int J Cancer; 2016 Mar; 138(6):1516-27. PubMed ID: 26437179 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]